These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681 [TBL] [Abstract][Full Text] [Related]
44. A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. Huang DB; File TM; Torres A; Shorr AF; Wilcox MH; Hadvary P; Dryden M; Corey GR Clin Ther; 2017 Aug; 39(8):1706-1718. PubMed ID: 28756068 [TBL] [Abstract][Full Text] [Related]
53. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Kollef MH; Rello J; Cammarata SK; Croos-Dabrera RV; Wunderink RG Intensive Care Med; 2004 Mar; 30(3):388-94. PubMed ID: 14714107 [TBL] [Abstract][Full Text] [Related]
54. For nosocomial vancomycin-resistant enterococcal infections: the ounce of prevention or the pound of cure? Farr BM Clin Infect Dis; 2004 Apr; 38(8):1116-8. PubMed ID: 15095216 [No Abstract] [Full Text] [Related]
55. Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empirical therapy. Costa SF; Newbaer M; Santos CR; Basso M; Soares I; Levin AS Int J Antimicrob Agents; 2001 Feb; 17(2):147-50. PubMed ID: 11165120 [TBL] [Abstract][Full Text] [Related]
56. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer? Tsoulas C; Nathwani D Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913 [TBL] [Abstract][Full Text] [Related]
57. A position paper on the treatment of hospital acquired pneumonia (HAP): do we need guidelines? Ramphal R Acta Clin Belg; 2002; 57(4):202-6. PubMed ID: 12462796 [No Abstract] [Full Text] [Related]
59. Ceftobiprole for the treatment of pneumonia: a European perspective. Liapikou A; Cillóniz C; Torres A Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697 [TBL] [Abstract][Full Text] [Related]
60. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]